Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.

ABSTRACT:

Objectives

Drug-resistant TB remains a public health challenge. Rifamycins are among the most potent anti-TB drugs. They are known to target the RpoB subunit of RNA polymerase; however, our understanding of how rifamycin resistance is genetically encoded remains incomplete. Here we investigated rpoB genetic diversity and cross-resistance between the two rifamycin drugs rifampicin and rifabutin.

Methods

We performed WGS of 1003 Mycobacterium tuberculosis clinical isolates and determined MICs of both rifamycin agents on 7H10 agar using the indirect proportion method. We generated rpoB mutants in a laboratory strain and measured their antibiotic susceptibility using the alamarBlue reduction assay.

Results

Of the 1003 isolates, 766 were rifampicin resistant and 210 (27%)

SUBMITTER: Farhat MR 

PROVIDER: S-EPMC6524487 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature